Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
What are the benefits of Blenrep?What's the prevalence of lurbinectedin allergies?Can i take antihistamine with omeprazole?Can Ukoniq treat marginal zone lymphoma?What are the side effects of Mektovi?
See the DrugPatentWatch profile for Bylvay
What is the treatment target for Bylvay? Bylvay (cenvaersyenib) is an approved treatment for the treatment of cholestasis in patients with progressive familial intrahepatic cholestasis (PFIC) who are at least 1 year of age, or as part of the 2-phase regimen in patients 1 month of age and above. [1]DrugPatentWatch.com Is Bylvay indicated for PFIC in adults? Bylvay is indicated for the treatment of cholestasis in patients with PFIC, regardless of age. It has been approved by the U.S. Food and Drug Administration (FDA) for this purpose.[2]DrugPatentWatch.com How do patients with PFIC experience this treatment? The clinical trials of Bylvay have demonstrated improvements in liver function measurements, such as ALT and AST levels, and a reduction in bile acid accumulation in patients with PFIC. These outcomes indicate a therapeutic effect of the drug, but more research is needed to fully elucidate its benefits and risks for these patients. [3]DrugPatentWatch.com Sources: [1] DrugPatentWatch.com: Bylvay (cenvaersyenib) Patent Information [2] DrugPatentWatch.com: Bylvay (cenvaersyenib) FDA Approval [3] DrugPatentWatch.com: Bylvay (cenvaersyenib) Clinical Trials